Tricida Inc

Tricida — Investor Presentation (April 2020)

47 slides from Tricida's investor presentation, Apr 15, 2020

  1. Slide 1: Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease

    Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation April 2020

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Examples of such statements include our plans, beliefs,

  3. Slide 3: Our Goals for Veverimer

    Our Goals for Veverimer* A Drug Candidate for the Treatment of Metabolic Acidosis in Patients with CKD Veverimer Is Under Review by the FDA with a PDUFA Goal Date of August 22, 2020 First and ONLY Disease Improve How Patients FDA-Approved Therapy Modifying Feel and Function Significant unmet medical

  4. Slide 4: Eight Things to Know About Metabolic Acidosis

    Eight Things to Know About Metabolic Acidosis

  5. Slide 5: 1. Metabolic Acidosis is Commonly Caused by Kidney Disease

    1. Metabolic Acidosis is Commonly Caused by Kidney Disease Diseased Kidneys Lose Capacity to Excrete Acid Serum Bicarbonate Levels Fall acid Normal 22 – 29 Range mEq/L Serum bicarbonate Acid is generated Diseased kidneys An increase in acid Metabolic 12 – <22 from dietary sources lose capacity leads

  6. Slide 6: 2. Metabolic Acidosis is Highly Prevalent in CKD

    2. Metabolic Acidosis is Highly Prevalent in CKD ~ 3 Million Patients with Metabolic Acidosis and CKD in the United States ~600,000 ~1.1 Million > % ~1.4 Million 30 18% 9% Stage 3a Stage 3b Stage 4 & 5 *Stage 5 pre-dialysis patients. Data on file. NHANES 1999-2004 reports prevalence of CKD Stages 3

  7. Slide 7: 3. Metabolic Acidosis Can Impact Kidney, Bone and Muscle Health

    3. Metabolic Acidosis Can Impact Kidney, Bone and Muscle Health Metabolic Acidosis is Associated with an Increased Risk of CKD Progression and Adverse Effects On Bone and Muscle Reduced Renal Acid Secretion Increased Risk of CKD Leads to Acid Buildup Progression and Mortality Acid Buffering Leads to

  8. Slide 8: 4. Metabolic Acidosis is Linked to Worsening Kidney Disease

    4. Metabolic Acidosis is Linked to Worsening Kidney Disease Increased Acid Excretion Augmented ammoniagenesis and enhanced proton secretion Renal Impairment Metabolic Persistent Acid Retention Kidney disease Sustained expression of ET-1, Acidosis progression aldosterone and angiotensin II Further Di

  9. Slide 9: 5. Increasing Serum Bicarbonate Translates to Clinical Benefit

    5. Multiple Academic Studies Show that Increasing Serum Bicarbonate Translates to Clinical Benefit Forest Plot Shows Slower Decline in eGFR at the End of Study Period with Oral Alkali Supplementation or Reduction of Dietary Acid Intake Oral alkali Dietary intervention Navaneethan et al., CJASN, 2019

  10. Slide 10: 6. Kidney Disease Guidelines Recommend Treating Metabolic Acidosis

    6. National and International Kidney Disease Guidelines Recommend Treating Metabolic Acidosis CKD Practice Guidelines Suggest Treatment if Serum Bicarbonate Levels are Below 22 mEq/L “We suggest that in people with CKD and “In CKD Stages 3, 4, and 5, the serum level serum bicarbonate concentrations

  11. Slide 11: 7. Metabolic Acidosis is Undertreated

    7. Metabolic Acidosis is Undertreated The Majority of Patients with Metabolic 100% Acidosis are NOT treated 90% 80% % of 70% Patients 60% Receiving 50% Oral Alkali 40% Therapy 30% 20% 15% < 10% 10% < 3% < 6% 0% CRIC Study Tangri 2020 TRCA-301 Tangri 2019 Dobre 2013 Dobre M et al., AJKD, 2013. Tangri

  12. Slide 12: 8. Oral Alkali Supplements Can Deliver Unacceptable Sodium Loads

    8. Current Treatments for Metabolic Acidosis Have Limitations: Oral Alkali Supplements Can Deliver Unacceptable Sodium Loads KDIGO guidelines recommend restricting sodium intake to <2 g per day in patients with CKD Other guidelines for common co-morbid diseases associated with CKD also recommend res

  13. Slide 13: 8. Oral Alkali Supplements Can Have Adverse Systemic Effects

    8. Current Treatments for Metabolic Acidosis Have Limitations: Oral Alkali Supplements Can Have Adverse Systemic Effects Adverse Systemic Effects Mean Changes (Day 1 to Day 5) in Weight and Systolic Blood Pressure • The volume effects (e.g., blood pressure, sodium retention) of Change in Body Change

  14. Slide 14: 8. Sodium from Oral Alkali May Inhibit Hypertension Therapies

    8. Current Treatments for Metabolic Acidosis Have Limitations Sodium from Oral Alkali May Inhibit the Efficacy of Common Hypertension Therapies Sodium Attenuates the Beneficial Effects of ARBs and ACEi ACEi therapy Post-hoc analysis of RENAAL and IDNT trials Post-Hoc Analysis of REIN Trials Risk of

  15. Slide 15: 8. Oral Alkali Supplements Not Established Safe and Efficacious

    8. Current Treatments for Metabolic Acidosis Have Limitations: Oral Alkali Supplements Have Not Been Established to be Safe and Efficacious (Not FDA-Approved) BiCARB Multi-Center, Double-Blind, Placebo Controlled, Randomized Trial • Efficacy Summary • Population: 300 subjects enrolled at 27 study si

  16. Slide 16: Metabolic Acidosis: Three Key Takeaways

    Metabolic Acidosis: Three Key Takeaways Metabolic acidosis is common, harmful 1 and needs to be treated Metabolic acidosis is both a complication and an underlying cause of kidney disease 2 progression There is an urgent need for an FDA-approved 3 therapy to treat chronic metabolic acidosis 16

  17. Slide 17: Urgent Need for an FDA-Approved Therapy to Treat Chronic Metabolic Acidosis

    There is an Urgent Need for an FDA-Approved Therapy to Treat Chronic Metabolic Acidosis Currently Available Approaches Have Limitations and Are Not Widely Used • Neutralize acid with oral alkali supplements • Decrease acid intake with dietary intervention Veverimer: A Potential New Approach to Treat

  18. Slide 18: Designed to Bind and Remove Acid in the GI Tract

    Veverimer: Designed to Bind and Remove Acid in the GI Tract to Raise Serum Bicarbonate and Treat Metabolic Acidosis 18

  19. Slide 19: Designed to Bind and Remove HCl with High Capacity and Selectivity

    Veverimer: Designed to Bind and Remove HCl with High Capacity and Selectivity High Binding Capacity High Binding Selectivity NH2 NH2 veverimer Non-absorbed polymer GI Anions Ranked by Size NH2 NH2 Oral Ingestion Oral H+ Bile Acids NH + NH + + Fatty Acids 3 3 Binds protons (H ) and then selectively v

  20. Slide 20: Ease of Administration

    Veverimer: Ease of Administration* Once-a-day dosing Orally administered as a suspension in water 3 g, 6 g or 9 g dose sizes 2 oz. Water No observed drug-drug interactions** *Targeted profile if approved ** Data on file 20

  21. Slide 21: Being Reviewed through the Accelerated Approval Program

    Veverimer: Being Reviewed through the Accelerated Approval Program – PDUFA Goal Date of August 22, 2020 Accelerated Approval Veverimer NDA Accepted for Review Program Requirements through the Accelerated Approval Program Increasing blood bicarbonate may Treats a Serious, slow progression to ESRD for

  22. Slide 22: Clinical Trial Program

    Veverimer: Clinical Trial Program Completed Clinical Trials Postmarketing Trial TRCA-101* Successful 2-week, randomized, double-blind, Initiated enrollment in 4Q 2018 placebo-controlled Phase 1/2 trial, 3 doses and 2 dosing regimens of veverimer or placebo Evaluate the efficacy and safety of veverim

  23. Slide 23: TRCA-301 and TRCA-301E Trial Results Published in The Lancet

    Veverimer: TRCA-301 and TRCA-301E Trial Results Published in The Lancet TRCA-301 Results TRCA-301E Results 23

  24. Slide 24: TRCA-301/301E Trial Design

    Veverimer: TRCA-301/301E Trial Design Study TRCA-301 Study TRCA-301E Treatment Period Treatment Period Veverimer 6 g QD (n=124) Veverimer 3-9 g QD (n=114) Fixed 6 g QD until Week 4 217 patients with eGFR 20-40 2 mL/min/1.73m R Dose adjustments Safety and serum 4:3 allowed * Follow-up bicarbonate 12-

  25. Slide 25: TRCA-301: Baseline Disease Characteristics

    Veverimer: TRCA-301: Baseline Disease Characteristics Veverimer Placebo Medication Veverimer Placebo N=124 N=93 Use N=124 N=93 29 28 ACE inhibitors / ARBs 67% 82% Baseline eGFR, mean mL/min/1.73m2 mL/min/1.73m2 Diuretics 60% 63% Baseline serum 17 mEq/L 17 mEq/L bicarbonate, mean Calcium channel bloc

  26. Slide 26: Summary of TRCA-301/301E Clinical Trial Results

    Veverimer: Summary of TRCA-301/301E Clinical Trial Results TRCA-301 Veverimer-Treated Subjects Experienced a Mean TRCA-301 / TRCA-301E Increase from Baseline in Serum Bicarbonate of 4.5 mEq/L Prespecified Time-to-Event Analyses (52 Weeks) 21.7 65% Reduction in the Annualized Event Rate for Veverimer

  27. Slide 27: TRCA-301E Prespecified Analyses

    Veverimer: TRCA-301E Prespecified Analyses 1) Kidney Disease Quality of Life (KDQOL) Physical Function Survey ̶ A validated questionnaire designed to assess kidney disease-specific health-related quality of life ̶ Subjects responded to the 10 KDQOL questions related to physical function during daily

  28. Slide 28: Improvement in Patient-Reported Physical Function Over One Year

    Veverimer: Improvement in Patient-Reported Physical Function Over One Year (KDQOL Physical Function Domain) 15 p<0.0001 Veverimer (N=114) Placebo (N=82) 11.42*11.42 Mean 10 p=0.0396 p=0.0177 Change 7.80 from 6.49 Baseline in KDQOL 5 Physcial Function Domain 2.11 0 1.16 Functioning Physical Improved

  29. Slide 29: Improvement in Measured Physical Functioning Over One Year

    Veverimer: Improvement in Measured Physical Functioning Over One Year (Repeated Chair Stand Test) 2 Veverimer (N=114) Placebo (N=82) 1 ImprovedPhysical Functioning 0 p=0.0017 p<0.0001 p<0.0001 Mean -1 -1.25 -1.19 Change --1.41.42 from -2 Baseline to -2.25 Complete -3 Repeated Chair Test, -4 -3.71 Se

  30. Slide 30: Reduction in Composite of Mortality and Kidney Disease Progression (DD50)

    Veverimer: Reduction in a Composite of Mortality and Kidney Disease Progression Over One Year (DD50) TRCA-301 / TRCA-301E Study Results Pre-Specified Time-to-Event Analyses (52 Weeks) Kaplan-Meier Plot of Time to First Occurrence of Death, Renal Replacement Therapy or ≥50% Decline in eGFR 4% DD50 in

  31. Slide 31: TRCA-301/301E Safety Summary

    Veverimer: TRCA-301/301E Safety Summary TRCA-301 TRCA-301E Veverimer Placebo Veverimer Placebo (n=124) (n=93) (n=114) (n=82) Discontinued prematurely 4.0% 4.3% 2.6% 9.8% Serious adverse events (none assessed to be related to 2.4% 2.2% 1.8% 4.9% study drug) Gastrointestinal adverse events 16.9% 8.6%

  32. Slide 32: Our Goal is to Launch Veverimer in the United States

    Our Goal is to Launch Veverimer in the United States for Treatment of Patients with CKD and Metabolic Acidosis Treated by Nephrologists 32

  33. Slide 33: Metabolic Acidosis is a Significant US Market Opportunity

    Metabolic Acidosis is a Significant US Market Opportunity 3,000,000 Increased Awareness Patients with CKD and drives higher metabolic acidosis diagnosis and treatment Metabolic Acidosis Expansion 1,100,000 beyond nephrologists provides additional opportunity Patients Under Physician Care Focus on pa

  34. Slide 34: Patients Treated By a Relatively Small Number of Nephrologists

    A High Number of Patients with Metabolic Acidosis Are Treated By a Relatively Small Number of Nephrologists Highly Concentrated Market 100% 80% of Potential Target Patient Population 80% 60% 40% 20% Cumulative % Potential 0% ~5,000 Nephrologists Cumulative % of nephrologists with highest number of p

  35. Slide 35: We Will Target ~5,000 Community Nephrologists at Launch

    We Will Target ~5,000 Community Nephrologists at Launch Optimize Reach with 2 Regional Managers, 10 Division Heads and 80 to 85 Strategic Account Managers # Nephrologist Symphony Health Solutions IDV® 35

  36. Slide 36: Nephrologists Believe There is a Link Between Metabolic Acidosis and Health

    High-Prescribing Nephrologists Believe There is a Link Between Metabolic Acidosis and Kidney, Bone and Muscle Health Progression of CKD Muscle health Bone health 84% of respondents believe that 86% of respondents believe that 98% of respondents believe that treating metabolic acidosis helps to treat

  37. Slide 37: Expanding our Disease Awareness Campaign

    Expanding our Disease Awareness Campaign Website and Neph+ App Digital Ads and Congresses Social Media Engagement ASN Kidney Week 2019 >1,000 Engagements with HCPs www.metabolicacidosisinsights.com Now ranked 1st on Google search 37

  38. Slide 38: Increasing Awareness Through Publications and Posters

    Increasing Awareness of Veverimer and Metabolic Acidosis Through Publications and Posters Veverimer Metabolic Acidosis TRCA-301 Results TRCA-301E Results March 2019 June 2019 Jun 2019: Tolerance to Mar 2019: Clinical Jul 2019: Effects of Veverimer versus placebo in Long-term safety and efficacy of S

  39. Slide 39: Positive Reaction to Profile and Anticipated Adoption

    Veverimer: Positive Reaction to Profile and Anticipated Adoption Supports Market Opportunity to Address a High Unmet Need Nephrologists Were Asked about Their Nephrologists Were Asked to Estimate Likelihood of Prescribing Veverimer* Veverimer Share at One Year* 79% Would Definitely or 52% Probably P

  40. Slide 40: Engaging with Payers to Facilitate Optimal Coverage

    Engaging with Payers to Facilitate Optimal Coverage $$$ $$$ $$$$ $$$ Managed Market Employing Multiple Payer Advisory Team Actively Meeting Avenues for Handling Board Meeting with Payers Prior Authorizations • Met with 10 payers representing ~100 • Field-based payer team of 12 • Mirror nephrologists

  41. Slide 41: Ongoing Payer Discussions Include Health Impact of Metabolic Acidosis

    Ongoing Payer Discussions Include Health Impact of Metabolic Acidosis Supportive Data from Analysis of Major Payer Database Shows Significant Health Impact of Metabolic Acidosis Over a Two-Year Period 3X 3.6X 1.5X Higher Likelihood Higher Likelihood of Higher Likelihood to Progress of Death Starting

  42. Slide 42: Ongoing Payer Discussions Include HEOR Analysis

    Ongoing Payer Discussions Include HEOR Analysis Compelling Health Economic Outcomes Research (HEOR) Message for Payers Impact of metabolic acidosis comparing Impact of increase in serum bicarbonate all-cause cost in an acidotic vs. as a continuous variable in combined non-acidotic population acidoti

  43. Slide 43: Payer Mix Represents ~62% of Target Population

    Patients with Commercial, Medicare with Subsidy, Medicaid and VA/DOD Patients Represent ~62% of Target Population Anticipated Payer Mix in Target Population 1% VA/DOD 5% VA/ Uninsured DODCash 10% Medicaid Medicaid33% Over half of the initial targeted patients with Medicare with CKD and metabolic aci

  44. Slide 44: Multi-Billion Revenue Opportunity in the US

    Veverimer: Multi-Billion Revenue Opportunity in the US with a Focus on the Nephrology Specialty US Revenue Metrics Est. WAC price: 3,000,000 ~$2,000 – $3,000/month Patients with CKD and Est. net price (~30% GtN): ~$1,400 – $2,100/month Metabolic Acidosis Est. compliance: 65% (~8 months/year) 1,100,0

  45. Slide 45: Worldwide Patent Estate

    Veverimer: Worldwide Patent Estate United States Europe Rest of World • Six issued Orange Book • Three issued patents • Issued patents in Australia, eligible patents Hong Kong, Japan, Mexico and • Several pending Russia • Several pending patent patent applications applications • Corresponding pendin

  46. Slide 46: Strong Financial Position

    Strong Financial Position ~ $355 million year-end cash, cash equivalents and investments as of December 31, 2019 $60 million currently drawn under a $200 million debt facility with Hercules (including $20 million drawn in December 2019) – Additional draw down availability of: • $15 million prior to

  47. Slide 47: Thank You

    THANK YOU IRICIDA

Tricida — Investor Presentation (April 2020) on 6ix